Patterns and economic burden of hospitalizations and exacerbations among patients diagnosed with idiopathic pulmonary fibrosis

Journal of Managed Care and Specialty Pharmacy

Volumn 22, Issue 4, 2016, Pages 414-423

  Yu, Yanni F ^a   Wu, Ning ^c   Chuang, Chien Chia ^d   Wang, Rosa ^f   Pan, Xiaoyun ^f   Benjamin, Nicole N ^f   Devercelli, Giovanna ^b   Coultas, David B ^e  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b Shire Pharmaceuticals   (United States)

^c BIOGEN   (United States)

^d DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^e VETERANS AFFAIRS PORTLAND HEALTH CARE SYSTEM   (United States)

^f EVIDERA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; ECONOMIC ASPECT; FEMALE; FIBROSING ALVEOLITIS; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INCIDENCE; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RARE DISEASE; RETROSPECTIVE STUDY; VERY ELDERLY; BIOPSY; COHORT ANALYSIS; COST OF ILLNESS; ECONOMICS; FACTUAL DATABASE; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; PATHOPHYSIOLOGY; REIMBURSEMENT; STATISTICS AND NUMERICAL DATA; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; BIOPSY; COHORT STUDIES; COST OF ILLNESS; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84963722568     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2016.22.4.414     Document Type: Article

References (29)

1. Gulati M. Diagnostic assessment of patients with interstitial lung disease. Prim Care Respir J. 2011;20(2):120-27.
2. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One. 2007;30;2(5):e482.
3. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636-43.
4. Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med. 2008;19(4):227-35.
5. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C; IPFnet Investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73.
6. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005;128(3):1475-82.
7. Kim DS. Acute exacerbations in patients with idiopathic pulmonary fibrosis. Respir Res. 2013;14:86.
8. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040-47.
9. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27(1):143-50.
10. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
11. Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis. Clin Chest Med. 2012;33(1):59-68.
12. Kondoh Y, Taniguchi H, Katsuta T, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):103-10.
13. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356-63.
14. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-19.
15. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996;49(12):1429-33.
16. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol. 2000;29(5):891-98.
17. Marshall WJ, Bangert SK. Clinical Biochemistry: Metabolic and Clinical Aspects. 2nd ed. London: Churchill Livingstone; 2008.
18. Baillargeon J, Wang Y, Kuo YF, Holmes HM, Sharma G. Temporal trends in hospitalization rates for older adults with chronic obstructive pulmonary disease. Am J Med. 2013;126(7):607-14.
19. Abudagga A, Sun SX, Tan H, Solem CT. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis. Int J Chron Obstruct Pulmon Dis. 2013;8:175-85.
20. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-82.
21. Brown AW, Fischer CP, Shlobin OA, et al. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest. 2015;147(1):173-79.
22. Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ. 2012;15(5):829-35.
23. Collard HR, Chen SY, Yeh WS, et al. Health care utilization and costs in idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc. 2015;12(7):981-87.
24. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortalityrelated factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124(2):459-67.
25. Institute of Medicine (IOM). A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases. Washington, DC: National Academies Press; 2011.
26. Evaluating the effectiveness of prednisone, azathioprine, and n-acetylcysteine in patients with IPF (PANTHER-IPF). Identifier: NCT00650091. ClinicalTrials.gov. 2015. Available at: https://clinicaltrials. gov/ct2/show/NCT00650091. Accessed January 21, 2016.
27. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3-19.
28. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810-16.
29. Sun P, Seftel A, Swindle R, Ye W, Pohl G. The costs of caring for erectile dysfunction in a managed care setting: evidence from a large national claims database. J Urol. 2005;174(5):1948-52.